Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
Guardant Health (Nasdaq: GH) has announced a strategic collaboration with Pfizer (NYSE: PFE) to advance cancer therapy development using the Guardant Infinity™ smart liquid biopsy platform. The multi-year global partnership will:
- Implement Guardant's liquid biopsy tests in Pfizer's global clinical studies
- Assess circulating tumor DNA (ctDNA) as a surrogate endpoint for therapy response monitoring
- Evaluate blood-based epigenomic analyses
The agreement includes access to Guardant's liquid biopsy tests in China for Pfizer's global clinical trials with Chinese cohorts, building on Guardant's existing partnership with Adicon Holdings announced in July 2022.
Pfizer (NYSE: PFE) has announced its second-quarter 2025 dividend declaration. The company's board of directors has approved a quarterly cash dividend of $0.43 per share, which will be paid on June 13, 2025, to shareholders of record as of May 9, 2025. This marks Pfizer's 346th consecutive quarterly dividend payment, highlighting the company's long-standing commitment to shareholder returns.
Pfizer will present significant oncology research at the ASCO 2025 Annual Meeting, featuring over 60 abstracts including 15 oral presentations. Two late-breaking presentations will showcase: primary analysis of BREAKWATER study investigating BRAFTOVI combination therapy in colorectal cancer, and VERITAC-2 study results for vepdegestrant in breast cancer.
Key highlights include five-year survival data for XTANDI in prostate cancer, first combination data for ELREXFIO in multiple myeloma, and novel antibody-drug conjugates (ADCs) research. The company will present Phase 1 data on two investigational ADCs - sigvotatug vedotin for lung and head/neck cancers, and PDL1V for head/neck cancers, both in combination with pembrolizumab.
The presentations support Pfizer's goal of delivering eight breakthrough cancer medicines by 2030, with nine new pivotal Phase 3 trials planned for 2025.
Pfizer (PFE) announced that the CDC's Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for RSV vaccines to include adults aged 50-59 at increased risk of RSV-associated lower respiratory tract disease (LRTD). This expansion specifically includes ABRYSVO®, which received FDA approval in October 2024 for preventing RSV-associated LRTD in at-risk adults aged 18-59.
According to CDC data, approximately 15,000-20,000 RSV-associated hospitalizations occur annually in U.S. adults aged 50-59. The highest risk affects those with underlying conditions such as obesity, cardiovascular disease, diabetes, COPD, asthma, and other chronic or immunocompromising conditions. ABRYSVO currently holds the broadest indication among RSV vaccines, covering older adults, at-risk adults 18 and older, and pregnant women.
Pfizer (NYSE: PFE) has announced the discontinuation of danuglipron, its oral GLP-1 receptor agonist being developed for chronic weight management. While dose-optimization studies of once-daily formulations met key pharmacokinetic objectives, the decision came after a participant experienced potential drug-induced liver injury, which resolved after discontinuing the treatment.
The studies involved over 1,400 participants, with liver enzyme elevations generally aligned with approved agents in the same class. Despite this setback, Pfizer remains committed to advancing treatments for cardiovascular and metabolic diseases, including obesity, through their oral GIPR antagonist candidate and other early-stage obesity programs.
Pfizer (NYSE: PFE) has announced its virtual 2025 Annual Meeting of Shareholders, scheduled for April 24, 2025, at 9:00 a.m. EDT. Shareholders can access the meeting through https://meetnow.global/PFE2025, with login available from 8:45 a.m. EDT.
Participants will need a control number from their proxy card, voting instruction form, or notice to ask questions and vote during the meeting. Questions can be submitted in advance until 5:00 p.m. EDT on April 22. While most shareholders can vote during the meeting, some beneficial owners may need to obtain a legal proxy and pre-register.
The meeting will also be available in listen-only mode without a control number, and a replay will be accessible for up to one year at https://investors.pfizer.com/Investors/Events--Presentations. The virtual format ensures shareholders have comparable rights and opportunities as an in-person meeting.
Pfizer (NYSE: PFE) has received European Commission approval for an expanded indication of its RSV vaccine ABRYSVO®. The authorization now includes prevention of lower respiratory tract disease (LRTD) in adults aged 18-59, extending beyond its previous approval for those 60 and older.
ABRYSVO becomes the first and only RSV vaccine approved in the European Union for non-pregnant adults aged 18-49. The vaccine now offers the broadest RSV indication in the EU, covering both active immunization for adults 18 and older, and passive protection for infants through maternal immunization during pregnancy.
The approval is supported by the phase 3 clinical trial MONeT (NCT05842967), which evaluated the vaccine's safety, tolerability, and immunogenicity in adults 18-59 years with risk factors for RSV-associated LRTD. RSV causes approximately 158,000 adult hospital admissions annually in the EU.
Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, has appointed Jon Coleman as Chief Commercial Officer. Coleman brings over 30 years of global commercial leadership experience and will oversee Dexcom's global commercial organization, including sales, marketing, and customer experience.
Coleman previously served as an executive officer at Masimo (NASDAQ: MASI) for 15 years, where he was president of commercial teams. He managed worldwide hospital sales, OEM, alternate care sales, clinical teams, and customer service. Prior to Masimo, Coleman held leadership positions at Pfizer (NYSE: PFE) Consumer Healthcare, including vice president and general manager of Canada and the Caribbean region, with additional experience in Asia and Latin America.
Throughout his career, Coleman has demonstrated success in scaling operations, developing innovative products, entering new markets, and delivering strong growth performance.
Pfizer (NYSE: PFE) has announced a conference call with investment analysts scheduled for April 29, 2025, at 10:00 a.m. EDT. The call will provide updates on the company's First Quarter 2025 Performance Report, which will be released that morning.
Investors and the public can access the webcast through www.pfizer.com/investors. Participants can also join via phone by dialing 800-456-4352 (US/Canada) or 785-424-1086 (international) using passcode '67619'. The webcast replay and transcript will be available on Pfizer's investor website within 24 hours and remain accessible for 90 days.
Pfizer, with a 175-year legacy, continues its mission of developing innovative medicines and vaccines. The company emphasizes its commitment to quality healthcare, global wellness, and breakthrough therapies that address critical diseases.
ViiV Healthcare has announced groundbreaking results from implementation studies for their HIV prevention injectable Apretude and treatment injectable Cabenuva at CROI 2025. The studies demonstrated remarkable effectiveness with zero HIV acquisitions reported in nearly 4,000 people using Apretude for prevention.
The PILLAR study, involving 201 participants across 17 U.S. clinics, showed zero HIV cases over 12 months, with 72% persistence rate. The ImPrEP CAB Brazil study of 1,447 participants demonstrated superior PrEP coverage with Apretude (96.2%) compared to oral PrEP (64.1%).
For Cabenuva treatment, real-world data from the OPERA analysis (n=2,485) showed 95% of patients maintained viral suppression, with only 1% experiencing confirmed virologic failure. The Trio Health cohort (n=928) similarly demonstrated 95% viral suppression maintenance, with 89% of injections administered on schedule.